Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms

Su Yin Lim; Helen Rizos

doi:10.1007/s00335-018-9757-4

Immune cell profiling in the age of immune checkpoint inhibitors

implications for biomarker discovery and understanding of resistance mechanisms

Su Yin Lim^*, Helen Rizos

^*Corresponding author for this work

Department of Biomedical Sciences

Research output: Contribution to journal › Review article

3 Citations (Scopus)

40 Downloads (Pure)

Abstract

Immunotherapy has changed the landscape of cancer treatment. The introduction of immune checkpoint inhibitors has seen tremendous success in improving overall survival of patients with advanced metastatic cancers and has now become the standard of care for multiple tumor types. However, efficacy of immune checkpoint blockade appears to be limited to immunogenic cancers, and even amongst immune-reactive cancers, response rates are low and variable between patients. Recent data have also demonstrated the rapid emergence of resistance to immune checkpoint inhibitors, with some patients progressing on treatment within one year. Significant research efforts are now directed at identifying predictive biomarkers and mechanisms of resistance to immune checkpoint blockade. These studies are underpinned by comprehensive and detailed profiling of the immune milieu. In this review, we discuss the utility and efficacy of immune cell profiling to uncover biomarkers of response and mechanisms of resistance to immune checkpoint inhibitors.

Original language	English
Pages (from-to)	866-878
Number of pages	13
Journal	Mammalian Genome
Volume	29
Issue number	11-12
Early online date	2 Jul 2018
DOIs	https://doi.org/10.1007/s00335-018-9757-4
Publication status	Published - Dec 2018

Bibliographical note

Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1007/s00335-018-9757-4Licence: CC BY

Publisher version (open access)Final published version, 2 MBLicence: CC BY

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms'. Together they form a unique fingerprint.

Cite this

Lim, S. Y., & Rizos, H. (2018). Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. Mammalian Genome, 29(11-12), 866-878. https://doi.org/10.1007/s00335-018-9757-4

@article{56dece48b4ee4f99a61faa3c34a78cd1,

title = "Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms",

abstract = "Immunotherapy has changed the landscape of cancer treatment. The introduction of immune checkpoint inhibitors has seen tremendous success in improving overall survival of patients with advanced metastatic cancers and has now become the standard of care for multiple tumor types. However, efficacy of immune checkpoint blockade appears to be limited to immunogenic cancers, and even amongst immune-reactive cancers, response rates are low and variable between patients. Recent data have also demonstrated the rapid emergence of resistance to immune checkpoint inhibitors, with some patients progressing on treatment within one year. Significant research efforts are now directed at identifying predictive biomarkers and mechanisms of resistance to immune checkpoint blockade. These studies are underpinned by comprehensive and detailed profiling of the immune milieu. In this review, we discuss the utility and efficacy of immune cell profiling to uncover biomarkers of response and mechanisms of resistance to immune checkpoint inhibitors.",

author = "Lim, {Su Yin} and Helen Rizos",

note = "Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2018",

month = "12",

doi = "10.1007/s00335-018-9757-4",

language = "English",

volume = "29",

pages = "866--878",

journal = "Mammalian Genome",

issn = "0938-8990",

publisher = "Springer, Springer Nature",

number = "11-12",

}

TY - JOUR

T1 - Immune cell profiling in the age of immune checkpoint inhibitors

T2 - implications for biomarker discovery and understanding of resistance mechanisms

AU - Lim, Su Yin

AU - Rizos, Helen

N1 - Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/12

Y1 - 2018/12

N2 - Immunotherapy has changed the landscape of cancer treatment. The introduction of immune checkpoint inhibitors has seen tremendous success in improving overall survival of patients with advanced metastatic cancers and has now become the standard of care for multiple tumor types. However, efficacy of immune checkpoint blockade appears to be limited to immunogenic cancers, and even amongst immune-reactive cancers, response rates are low and variable between patients. Recent data have also demonstrated the rapid emergence of resistance to immune checkpoint inhibitors, with some patients progressing on treatment within one year. Significant research efforts are now directed at identifying predictive biomarkers and mechanisms of resistance to immune checkpoint blockade. These studies are underpinned by comprehensive and detailed profiling of the immune milieu. In this review, we discuss the utility and efficacy of immune cell profiling to uncover biomarkers of response and mechanisms of resistance to immune checkpoint inhibitors.

AB - Immunotherapy has changed the landscape of cancer treatment. The introduction of immune checkpoint inhibitors has seen tremendous success in improving overall survival of patients with advanced metastatic cancers and has now become the standard of care for multiple tumor types. However, efficacy of immune checkpoint blockade appears to be limited to immunogenic cancers, and even amongst immune-reactive cancers, response rates are low and variable between patients. Recent data have also demonstrated the rapid emergence of resistance to immune checkpoint inhibitors, with some patients progressing on treatment within one year. Significant research efforts are now directed at identifying predictive biomarkers and mechanisms of resistance to immune checkpoint blockade. These studies are underpinned by comprehensive and detailed profiling of the immune milieu. In this review, we discuss the utility and efficacy of immune cell profiling to uncover biomarkers of response and mechanisms of resistance to immune checkpoint inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85049573662&partnerID=8YFLogxK

U2 - 10.1007/s00335-018-9757-4

DO - 10.1007/s00335-018-9757-4

M3 - Review article

VL - 29

SP - 866

EP - 878

JO - Mammalian Genome

JF - Mammalian Genome

SN - 0938-8990

IS - 11-12

ER -